XXXX -induced @entity146 disturbances: It is time for pharmacists to take notice.

@entity1 @entity162 @entity308 @entity146 @entity73 @entity228 @entity716 @entity933 @entity792 @entity288
UNASSIGNED: @entity288 are widely used to relieve signs and symptoms arising from many diseases, including common inflammatory and @entity792 affecting a number of organ systems. However, @entity288 also induce significant adverse effects; in particular, a range of severe @entity146 adverse effects may occur including @entity933 , @entity308 , @entity162 , @entity716 and @entity73 . These adverse effects occur in up to 60% of @entity1 taking @entity288 and recent studies show an increased rate of psychopathologies in this population. Long-term adverse effects on mood and behavior are severely debilitating, thereby influencing the quality of life, employment and health status of individuals taking @entity288 . Strategies used to manage @entity228 -induced @entity146 disturbances through psychotropic drugs vary significantly. This commentary summarizes existing literature on mechanisms underlying @entity228 -induced @entity146 adverse effects and evidence associated with using psychotropic drugs to manage these effects. Despite its importance, there is an absolute dearth in the literature examining pharmacists' understanding and perceptions of @entity146 adverse effects of @entity288 . Educational programs need to be implemented so that pharmacists can counsel @entity1 about how to recognize @entity228 -induced @entity146 disturbances. Physicians do not consistently alert @entity1 to watch for behavioral changes, and @entity1 may feel that mood changes they experience fall within the category of 'normal behavior,' and thus are less likely to report them. Given that @entity1 taking @entity288 usually have complex medical histories, discussions of adverse effects with pharmacists are vital to improve health outcomes in this population.
